Form 4: Charles River Laboratories Director George Llado Sr. Boosts Equity Holdings with New Stock and Option Grants

Charles River Laboratories International, Inc. Director George Llado Sr. has acquired 1,465 shares of common stock and 2,076 stock options as part of compensation, vesting over the next year.

Summary

• George Llado Sr., a Director at Charles River Laboratories International, Inc. (CRL), acquired common stock and stock options on May 21, 2025.
• He acquired 946 shares of common stock at a price of $134.98 per share. These unvested restricted stock units are set to vest on the earlier of May 21, 2026, or the business day prior to the company's next annual meeting of shareholders.
• An additional 519 shares of common stock were granted at $134.98 per share, made in lieu of director service fees for the term commencing May 20, 2025. These restricted stock units also vest on the earlier of May 21, 2026, or the business day prior to the company's next annual meeting of shareholders.
• He also acquired 2,076 stock options with an exercise price of $134.98 per share. These options become exercisable on the earlier of May 21, 2026, or the business day prior to the company's next annual meeting of shareholders, and expire on May 21, 2035.
• Following these transactions, George Llado Sr. beneficially owns 4,295 direct common shares (after the first acquisition) and 4,814 direct common shares (after the second acquisition), and 2,076 direct stock options.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a director, especially as compensation, generally indicates alignment of interests and confidence in the company's future, which is a positive signal for investors.

Positives

• Director George Llado Sr. increased his direct beneficial ownership in Charles River Laboratories, aligning his interests further with shareholders.
• The acquisition of shares and options represents compensation for director service, indicating ongoing commitment from key management personnel.

Risks

• The value of the acquired common stock and stock options is subject to market fluctuations, potentially impacting the director's compensation if the stock price declines.
• The vesting of restricted stock units and exercisability of stock options are contingent on future dates, meaning the full benefit is not immediately realized.

Future Outlook

The acquired restricted stock units and stock options are subject to future vesting and exercisability, primarily on May 21, 2026, or the business day prior to the company's next annual meeting of shareholders, indicating a future increase in the director's vested equity holdings.

Management Comments

• The grant was made in lieu of director service fees for the term commencing May 20, 2025.

Industry Context

This Form 4 filing is specific to Charles River Laboratories and its director compensation practices. While common across industries for executive and director compensation, it does not provide broader industry trends or competitive insights.

Corporate Governance

Related Party Transactions

• Acquisition of 519 common shares and 946 common shares (as restricted stock units) and 2,076 stock options by Director George Llado Sr. as part of his compensation, including grants in lieu of director service fees.

Stakeholder Impact

• Shareholders: Increased alignment of a director's financial interests with shareholder value due to increased equity ownership.
• Management: The compensation structure, including equity grants, incentivizes long-term performance and retention of key personnel.

Next Steps

• Vesting of 946 restricted stock units on the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Vesting of 519 restricted stock units on the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.
• Stock options for 2,076 shares becoming exercisable on the earlier of May 21, 2026, or the business day prior to the Company's next annual meeting of shareholders.

Key Dates

Keywords

Charles River Laboratories, CRL, Form 4, Insider Trading, Beneficial Ownership, Restricted Stock Units, Stock Options, Director Compensation, Equity Grant, SEC Filing